Fig. 6
From: Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma
WIP1 and PARP inhibition confers HCC cells synthetic lethal in vitro. A Cell viability of Hepa1-6 cells after Olaparib (48 h) or Veliparib (48 h) treatment with or without WIP1 knockdown was measured with MTS assay. B The apoptosis of Hepa1-6 cells after Olaparib (50 μM, 48 h) or Veliparib treatments with or without WIP1 knockdown was measured via flow cytometry with PI and annexin V–FITC double staining. C Cell viability of PLC/PRF/5 cells after Olaparib or Veliparib treatment with or without WIP1 inhibitor GSK2830371 was measured with MTS assay. D The apoptosis of PLC/PRF/5 cells after Olaparib or Veliparib treatment with or without WIP1 inhibitor GSK2830371 was measured via flow cytometry. E Cell viability of Hepa1-6 cells after Olaparib or Veliparib treatments with or without GSK2830371 treatment was measured with MTS assay. F The apoptosis of Hepa1-6 cells after Olaparib or Veliparib treatments with or without GSK2830371 treatment was measured via flow cytometry. G Cell viability of PLC/PRF/5 cells after Olaparib or Veliparib treatments with or without GSK2830371 treatment was measured with MTS assay. H The apoptosis of PLC/PRF/5 cells after Olaparib or Veliparib treatments with or without GSK2830371 treatment was measured via flow cytometry